Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway

Dermata Therapeutics, Inc.

Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.
Net proceeds of $7.6M from three 2023 financings partially offset $6.4M cash used in operations.
R&D expenses $4.1M in 2023 (down from $5.7M in 2022) due to lower clinical costs offset by CMC for Phase 3.
Enrollment initiated in DMT310 Phase 3 STAR-1 acne trial in Q4 2023; topline results expected Q1 2025.
Japanese patent issued for DMT410 for hyperhidrosis; partnership discussions ongoing.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dermata Therapeutics, Inc. reported financial results for full year ended December 31, 2023.

Period: full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-003500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.